Troglitazone-binding to Ldl and its glycated modifications its role in cell-catalysed and Cu-mediated Ldl-oxidation

Life Sciences

Volumn 67, Issue 6, 2000, Pages 695-707

  Sobal, G ^a   Sinzinger, H ^a   Menzel, E J ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

8 Epiprostaglandin F(2 ); Human umbilical vein endothelial cells; Low density lipoprotein; Oxidative modification; Thiazolidines; Troglitazone

Indexed keywords

COPPER; LOW DENSITY LIPOPROTEIN; THIAZOLIDINE DERIVATIVE; THIOBARBITURIC ACID; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 8 EPI PROSTAGLANDIN F2ALPHA; 8-EPI-PROSTAGLANDIN F2ALPHA; ANTIDIABETIC AGENT; CHROMAN DERIVATIVE; DRUG DERIVATIVE; GLYCOPROTEIN; MALONALDEHYDE; PROSTAGLANDIN F2 ALPHA; THIAZOLE DERIVATIVE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ACETYLATION; ARTICLE; CATALYSIS; CHROMATOPHORE; ENDOTHELIUM CELL; GLYCATION; HUMAN; HUMAN CELL; INSULIN RESISTANCE; LIPID OXIDATION; OXIDATIVE PHOSPHORYLATION; PROTEIN MODIFICATION; RECEPTOR BINDING; ADULT; BLOOD; CELL SURVIVAL; CYTOLOGY; DRUG EFFECT; LIPID PEROXIDATION; METABOLISM; OXIDATION REDUCTION REACTION; PROTEIN BINDING; VASCULAR ENDOTHELIUM;

ADULT; CELL SURVIVAL; CHROMANS; COPPER; DINOPROST; ENDOTHELIUM, VASCULAR; GLYCOPROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MALONDIALDEHYDE; OXIDATION-REDUCTION; PROTEIN BINDING; THIAZOLES; THIAZOLIDINEDIONES; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 0034705545     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(00)00662-7     Document Type: Article

References (34)

1. J.J. Nolan, B. Ludvik, P. Beerdsen, M. Joyce and J. Olefsky, N. Engl. J. Med. 331 1188-1193 (1994).
2. T. Fujiwara, S. Yoshioka , T. Yoshioka, I. Ushiyama and H. Horikoshi, Diabetes 37 1549-1558 (1988).
3. T.P. Ciaraldi, A. Gilmore, J.M. Olefsky, M. Goldberg and K.A. Heidenreich, Metabolism 39 1056-1062 (1990).
4. S.L. Suter, J.J. Nolan, P. Wallace, B. Gumbiner, J.M. Olefsky, Diabetes Care 15 193-203 (1992).
5. H. Watanabe, Chem. Pharm. Bulletin 45 1851-1855 (1997).
6. T. Yoshioka and T. Fujita, J. Pharmaceut. Soc. Japan 117 597-610 (1997).
7. J.P. Fulgencio, C. Kohl, J. Girard and J.P. Pegorier, Diabetes 45 1556-1562 (1996).
8. L. Cominacini, U. Garbin, A.M. Pastorino, A.F Pasini, A. Davoli, A. Rigoni and V. Locascio, Diabetologia 40 165-172 (1997).
9. Y. Nagasaka, K. Kaku, K. Nakamura and T. Kaneko, Biochem. Pharmacol. 50 1109-1111 (1995).
10. L. Cominacini, M.M.R. Young, A. Capriati, U. Garbin, A.F. Pasini, M. Campagnol, A. Davoli, A. Rigoni, G.B. Contessi and V. Lo Cascio, Diabetologia 4 1211-1218 (1997).
11. L. Cominacini, U. Garbin, A.F. Pasini, M. Campagnola, A. Davoli, E. Foot, G. Sighieri, A.M. Sironi, V. Lo Cascio, E. Ferrannini, Diabetes 47 130-133 (1998).
12. D. Steinberg, S. Parthasaraty, T.E. Carew, J.C. Khoo and J.L. Witztum, New Engl. J. Med. 320915-924 (1989).
13. S.J. Mao, M.T. Yates, A.E. Rechtin, R.I. Jackson and W.A. Van Sickle, J. Med. Chem. 34 298-302 (1991).
14. L. Cominacini, U. Garbin and A.M. Pastorino, Diabetes Res. 26 173-184 (1994).
15. C. Steiner, Adv. Exp. Med. Biol. 189 277-297 (1985).
16. V.W.M. Hinsbergh, M. Scheffer, L. Havekes and H.J.M. Kempen, Biochim. Biophys. Acta 878 49-64 (1986).
17. A. Festa, B. Schmölzer, G. Schernthaner and E.J. Menzel, Diabetologia 41 674-680 (1998).
18. J.A. Buege and S.D. Aust, Methods in Enzymology, L. Packer and A.N. Glazer (Eds), 56 302-310, Academic Press, San Diego (1978).
19. H. Horikoshi, T. Yoshioka, T. Kawasaki, K. Nakamura, N. Matsunuma, K. Yamaguchi, K. Sasahara (1994) troglitazone (CS-045), a new antidiabetic drug. Annu. Rep. Sankyo Res. Lab. 46 1-57 (1994).
20. J. Neumüller and E.J. Menzel, Methods in Molecular Biology, Vol.75: Basic Cell Culture Protocols. J.W. Pollard and J.M. Walker (Eds.), 399-425, Humana Press Inc., Totowa NJ (1997).
21. K. Kawai, Y. Kawasaki-Tokui, T. Odaka, F. Tsuruta, M. Kazui, H. Iwabuchi, T. Nakamura, T. Kinoshita, T. Ikeda, T. Yoshioka, T. Komai and K. Nakamura, Arzneimittelforsch./Drug Res. 47 356-368 (1997).
22. H. Bethge and H.U. Haring, Arzneimittelforsch./Drug Res. 48 97-119 (1998).
23. O. Al Rayyes and C.H. Floren, Diabetes 47 1193-1198 (1998).
24. N. Noguchi, H. Sakai, Y. Kato , J. Tsuchyia J, Y. Yamamoto, E. Niki, H. Horikoshi and T. Kodama, Atherosclerosis 123 227-234 (1996).
25. N.K. Gopaul, J. Nourooz-Zadeh, A.I. Mallet and E.E. Anggard, FEBS-lett. 348 297-300 (1994).
26. N.K. Gopaul, J. Nourooz-Zadeh, A.I. Mallet and E.E. Anggard, Biochem. Biophys. Res. Commun. 200 338-343 (1994).
27. S.M. Lynch, J.D. Morrow, L.J. Robrts and B. Frei, J. Clin. Invest. 93 998-1004 (1994).
28. R. Bucala, Z. Makita, T. Koschinsky, A. Cerami and H. Vlassara, Proc. Natl. Acad. Sci. USA 90 6434-6438 (1993).
29. M.A. Cathcart, A.K. Mc Nally, D.W. Morel, G.M. Chisholm, J. Immunol. 142 1963-1969 (1989).
30. M.K. Cathcart, A.K. Mc Nally and G.M. Chisholm, J. Lipid Res. 32 63-70 (1991).
31. W. Chamulitrat, M.F. Hughes, T.E. Eling and R.P. Mason, Arch. Biochem. Biophys. 290 153-159 (1991).
32. M. Ezaki, J.L. Witztum and D. Steinberg, J. Lipid Res. 36 1996-2004 (1995).
33. C. Jiang, A.T. Ting and B. Seed, Nature 391 82-86 (1998).
34. J. Ogawa, S. Takahashi, T. Fujiwara, J. Fukushige, T. Hosokawa, T. Izumi, S. Kurakata and H. Horikoshi, Life Sci. 65 1287-1296 (1999).